Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Vining

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Nature Communications|June 29, 2026
A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinomaLauren P Cobb, Yibo Dai, Max Molina Ayala, et al.
Nature|September 5, 2025
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Cancer Immunology Research|May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic CancerApostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Nature Communications|June 29, 2026
A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinomaLauren P Cobb, Yibo Dai, Max Molina Ayala, et al.
Nature|September 5, 2025
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Cancer Immunology Research|May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic CancerApostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.
Pageof 2